For the Inventor, By the Inventor

Enter assignee name

Seattle, WA, United States of America

The Biomembrane Institute

USPTO Granted Patents = 37

Forward Citations = 525

Loading Chart...

Loading Chart...

45 inventors (with patents filed for the assignee):

Sen-Itiroh Hakomori (18 out of 26 patents)

Sen-itiroh Hakomori (14 out of 25 patents)

Yasuyuki Igarashi (9 out of 15 patents)

4. Henrik Clausen (9 out of 9 patents)

5. Edward D Nudelman (8 out of 17 patents)

6. Mark R Stroud (7 out of 11 patents)

7. Steven B Levery (6 out of 9 patents)

8. Anil Singhal (6 out of 6 patents)

9. Kazuko Handa (5 out of 6 patents)

10. Hirofumi Okoshi (4 out of 4 patents)

11. Tatsushi Toyokuni (4 out of 4 patents)

12. Mary Ellen Salyan (3 out of 3 patents)

13. Mahammad N Ahmad (3 out of 3 patents)

14. Thomas J Kjeldsen (3 out of 3 patents)

15. Helio K Takahashi (3 out of 3 patents)

Core Competencies:

Glycosphingolipids

Monoclonal Antibodies

Carbohydrate Ligands

Tumor-Associated Antigens

Escherichia Coli

Liposomal Compounds

Sphingosine

Immune Induction

Histo-Blood Group

Vaccine Development

Cell Motility

Protein Kinase-C

37 patents: Sort by Forward Citations

1. 6294523 - Extended type 1 chain glycosphingolipids as tumor-associated antigens (2001-09-25),

2. 6133239 - Carbohydrate ligands (myelorollin) that cause E-selectin dependent cell (2000-10-17),

3. 6130205 - Method for determining susceptibility to Escherichia coli urinary tract (2000-10-10),

4. 6083929 - Extended type 1 chain glycosphingolipids as tumor-associated antigens (2000-07-04),

5. 5876715 - Antibodies that bind novel carbohydrate ligands (myelorollins) that (1999-03-02),

6. 5827830 - Plasmalopsychosines and plasmalocerebrosides (1998-10-27),

7. 5747048 - Monoclonal antibodies and vaccine development directed to human (1998-05-05),

8. 5660834 - Monoclonal antibodies and vaccine development directed to human (1997-08-26),

9. 5585473 - Compounds and methods for monosaccharide analysis (1996-12-17),

10. 5583160 - Methylsphingosine used to treat apoptosis (1996-12-10),

11. 5500215 - Methods for the production of antibodies and induction of immune (1996-03-19),

12. 5466716 - Liposomal trimethylsphingosine (1995-11-14),

13. 5421733 - Synthesis of Le.sup.x ; dimeric Le.sup.x (difucosyl Y.sub.2 ; III.sup.3 (1995-06-06),

14. 5418129 - Blood treatment method (1995-05-23),

15. 5403927 - Sequential removal of monosaccharides from the reducing end of (1995-04-04),

Company Overview

The Biomembrane Institute, based in Seattle, WA, specializes in the research and development of biomembrane technologies. This organization focuses on understanding and manipulating biological membranes, which are crucial for various applications in biotechnology and medicine. Their work encompasses areas such as drug delivery systems, biosensors, and membrane-based separation processes, contributing to advancements in health and environmental sustainability. The institute collaborates with academic and industry partners to drive innovation in membrane science.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

37 Patents

#66 in Seattle, WA

#207 in Washington

#9,262 in US

#18,281 in the World

Seattle, WA, United States of America

The Biomembrane Institute

Forward Citations = 525

45 inventors:

Sen-Itiroh Hakomori (18 out of 26 patents)

Sen-itiroh Hakomori (14 out of 25 patents)

Yasuyuki Igarashi (9 out of 15 patents)

4. Henrik Clausen (9 out of 9 patents)

5. Edward D Nudelman (8 out of 17 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: The Biomembrane Institute. Retrieved from https://idiyas.com/company/biomembrane-institute

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…